1. Pink Sheet
  2. >>Geography
  3. >>Europe

EU’s Unitary SPC System Must Maximize Access To Medicines & Not Block Generic Entry

 
• By Ian Schofield

A European Parliament committee says that some aspects of the EU’s proposed unitary supplementary protection certificate scheme could promote access to cheaper off-patent medicines while others could delay generic competition.

Patent skyline
The new uSPC system will offer wider extensions to effective patent life • Source: Shutterstock

It will be important to ensure that the European Commission’s proposals to increase access to medicines by linking regulatory rewards and incentives to EU-wide launch requirements are retained during the discussion of the pharmaceutical legislative reform at the parliament and Council of the EU, according to the European Parliament’s legal affairs committee (JURI).

If these proposals are weakened, “alternative provisions” could be considered that make eligibility for the grant of a supplementary protection certificate (SPC) dependent on compliance with specific EU marketing obligations,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

Non-User Fee Dollars Increased In US FDA’s Updated FY 2026 Budget Request

 
• By Derrick Gingery

The budget authority total, which is significantly higher than the amount floated in an April OMB draft document, suggests there may have been successful lobbying to increase FDA funding.

US ‘Most Favored Nation’ Pricing Could be Game Changer for Drug Access In Germany

 
• By Francesca Bruce

In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.

ICH Targets RWE, Rare Diseases, Biosimilars, ATMPs In New Guideline Push

 
• By Vibha Sharma

The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.